Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer. - Burston HE; Kent OA; Communal L; Udaskin ML; Sun RX; Brown KR; Jung E; Francis KE; La Rose J; Lowitz J; Drapkin R; Mes-Masson AM; et al. (The Journal of clinical investigation, 2021)